Resources

ACPGBI Position Statements: Management of Anal Fissure and Management of Acute Severe Colitis

These position statements were published as a Colorectal Disease supplement to Volume 9 in 2007.

The Association of Coloproctology of Great Britain and Ireland guideline on the management of anal fissure

ACPGBI presents the long-awaited Guideline on Anal Fissure Management. This is the first ACP guideline following the new rigorous processes. Although many of the recommendations haven’t changed, it gives evidence supporting clinic decisions,...

JAG consensus statements for training and certification in colonoscopy

Surveillance Colonoscopy for Inflammatory Bowel Disease: Why, When, How and What Next?

FIT in patients with signs or symptoms of suspected CRC: A joint guideline from ACPGBI and BSG

Authors (Guideline development group (GDG)) Kevin J Monahan / Michael M. Davies (Co-chairs, and lead authors). Co-authors: Muti Abulafi, Ayan Banerjea, Brian Nicholson, Ramesh Arasaradnam, Neil Barker, Sally Benton, Richard Booth, David Burling, Rachel Carten, Nigel D’Souza, James East, Jos Kleijnen, Michael Machesney, Maria Pettman, Jenny Pipe, Lance Saker, Linda Sharp, James Stephenson, Robert Steele.

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment (2021)

This is the second of a series of two articles reporting the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the management of adult patients with ulcerative colitis [UC]. The first article is focused on medical management, and the present article addresses medical treatment of acute severe ulcerative colitis [ASUC] and surgical management of medically refractory UC patients, including preoperative optimisation, surgical strategies, and technical issues. The article provides advice for a variety of common clinical and surgical conditions. Together, the articles represent an update of the evidence-based recommendations of the ECCO for UC.

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment (2021)

Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by colonic inflammation extending to a variable extent from the rectum. Care of the patient with UC requires appropriate input from across the multiprofessional team. These guidelines summarise the recommended medical treatment for adults with UC. Other ECCO guidelines consider the approach to UC diagnosis and monitoring,1–3 nursing care,4 management of disease complications,5–7 risk of infection,8 and technical aspects of surgery.9 This document was prepared as part of a process that also led to the publication of a related guideline with recommendations on the surgical care of the patients with UC and on the medical aspects of the management of the patient hospitalised with severe UC. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.

BAPEN-BSG position statements on intestinal failure

“The British Intestinal Failure Alliance (BIFA) is a multi-professional special interest group within the British Association for Parenteral and Enteral Nutrition (BAPEN). It focuses on temporary/reversible intestinal failure (IF) (Type 2 IF) and patients needing home parenteral support (nutrition and/or fluid) (Type 3 IF). The guidelines/recommendations and the position statements have all been written by the named authors and revised by the BIFA committee and BAPEN council. They aim to help staff working with patients with IF and those needing parenteral support.”

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease (2021)

The introduction and broad use of new immunosuppressive agents, including biologic agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease [IBD] in recent decades. With such immunosuppression, the potential for opportunistic infection is a key safety concern. Opportunistic infections pose particular problems for the clinician; they are potentially serious, often difficult to recognise, associated with appreciable morbidity or mortality, and are challenging to treat effectively. The first guideline on opportunistic infections was published in 20091 followed by an update in 2014.2 New evidence in this field and in vaccination strategies for immunosuppressed IBD patients led the European Crohn’s and Colitis Organization [ECCO] to update the previous consensus on opportunistic infections in IBD. The current document is focused on viral, mycobacterial, bacterial, fungal, and parasitic infections and on vaccination strategies for immunosuppressed IBD patients. The target audience includes IBD specialists, gastroenterologists, surgeons, and paediatricians.

ECCO guidelines on therapeutics disease in Crohn’s disease: Surgical treatment (2019)

This article is the second in a series of two publications relating to the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn’s disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also provides technical advice for a variety of common clinical situations. Both articles together represent the evidence-based recommendations of the ECCO for Crohn’s disease and an update of previous guidelines.